About
ATEM Capital (atemcap.com) is a NY-based Life Sciences investment fund that invests in breakthrough BioPharma / MedTech / Digital Health. Our prioritized therapeutic areas are platform technologies to cure oncology, autoimmune, cardiovascular, neurology diseases, and infections. In the last years, our team had over ten successful co-investments with the leading venture firms of the US and Europe: OrbiMed, Domain Associates, Canaan, ProQuest, LSP, Aisling Capital, MPM, Alta Partners, Frazier, Sofinnova, KPCB, as well as with the corporate venture firms: Pfizer, Roche, J&JDC, Novo, etc. Prioritized therapeutic areas are oncology, autoimmune diseases, rare diseases, and neurology. Our team members have extensive hands-on experience in product launches (over 40 products in the US and Europe), investments management (over $30 billion overall investment/liquidity), and exits of venture-backed companies.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- New York, US
Contact Information
Find more investors like ATEM
Search Investors